Dasatinib and Dexamethasone Combination Therapy Targets Myeloma and the Tumor Microenvironment

被引：0
|
作者：
Ramasamy, K. A. [1 ]
Macpherson, L. [1 ]
Mufti, G. [1 ]
Schey, S. [1 ]
Calle, Y. [1 ]
机构：
[1] Kings Coll London, London, England
来源：
CLINICAL LYMPHOMA & MYELOMA | 2009年 / 9卷
关键词：
D O I：
10.1016/S1557-9190(11)70692-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S116 / S117
页数：2
相关论文
共 50 条
  • [21] Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma
    Edvan de Queiroz Crusoe
    Patricia Maiso
    Diego Fernandez-Lazaro
    Laura San-Segundo
    Mercedes Garayoa
    Antonio Garcia-Gomez
    Norma C. Gutierrez
    Manuel Delgado
    Enrique Colado
    Jesus Martin-Sanchez
    Francis Y. Lee
    Enrique M. Ocio
    Annals of Hematology, 2012, 91 : 257 - 269
  • [22] Local targets for immune therapy to cancer: Tumor draining lymph nodes and tumor microenvironment
    Fransen, Marieke F.
    Arens, Ramon
    Melief, Cornelis J. M.
    INTERNATIONAL JOURNAL OF CANCER, 2013, 132 (09) : 1971 - 1976
  • [23] Thalidomide and dexamethasone combination for refractory multiple myeloma
    Dimopoulos, MA
    Zervas, K
    Kouvatseas, G
    Galani, E
    Grigoraki, V
    Kiamouris, C
    Vervessou, E
    Samantas, E
    Papadimitriou, C
    Economou, O
    Gika, D
    Panayiotidis, P
    Christakis, I
    Anagnostopoulos, N
    ANNALS OF ONCOLOGY, 2001, 12 (07) : 991 - 995
  • [24] Bortezomib in combination with dexamethasone for relapsed multiple myeloma
    Kropff, MH
    Bisping, G
    Wenning, D
    Volpert, S
    Tchinda, J
    Berdel, EW
    Kienast, J
    LEUKEMIA RESEARCH, 2005, 29 (05) : 587 - 590
  • [25] Combination therapy with onco-selective mRNA LNPs targets the complex immunosuppressive tumor microenvironment and is well tolerated at efficacious doses
    Kraus, Manfred
    Christmas, Rudy
    Addison, Tom A.
    Rybakova, Yulia
    Lee, Leona
    Xu, Jieni
    Krimmer, Mark
    Ozdemir, Cafer
    Yilmaz, Burak
    Erkul, Yusuf
    CANCER RESEARCH, 2023, 83 (07)
  • [26] Bortezomib therapy alone and in combination with dexamethasone for patients with previously untreated multiple myeloma.
    Jagannath, S
    Durie, B
    Wolf, J
    Camacho, E
    Irwin, D
    Lutzky, J
    McKinley, M
    Gabayan, E
    Mazumder, A
    Crowley, J
    Vescio, R
    Schenkein, D
    BLOOD, 2005, 106 (11) : 231A - 231A
  • [27] Combination therapy with thalidomide plus dexamethasone (THAL/DEX) for newly diagnosed myeloma (MM).
    Rajkumar, SV
    Hayman, SR
    Gertz, MA
    Dispenzieri, A
    Lacy, M
    Greipp, PR
    Geyer, S
    Itturia, N
    Fonseca, R
    Lust, JA
    Kyle, R
    Witzig, TE
    BLOOD, 2001, 98 (11) : 849A - 849A
  • [28] Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.
    Rajkumar, SV
    Hayman, S
    Lacy, MQ
    Dispenzieri, A
    Geyer, SM
    Kabat, B
    Zeldenrust, SR
    Kumar, S
    Greipp, PR
    Fonseca, R
    Lust, JA
    Russell, SJ
    Kyle, RA
    Witzig, TE
    Gertz, MA
    BLOOD, 2005, 106 (11) : 230A - 231A
  • [29] Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma
    Maharaj, Satish
    Chang, Simone
    Seegobin, Karan
    Serrano-Santiago, Ivan
    Zuberi, Lara
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (07) : 585 - 591
  • [30] Targeted intervention of tumor microenvironment with HDAC inhibitors and their combination therapy strategies
    Zhang, Wanli
    Ge, Luqi
    Zhang, Yiwen
    Zhang, Zhentao
    Zhang, Wen
    Song, Feifeng
    Huang, Ping
    Xu, Tong
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2025, 30 (01)
12345